Collapsing Mechanistic Models: An Application to Dose Selection for Proof of Concept of a Selective Irreversible Antagonist

被引:0
|
作者
Matthew M. Hutmacher
Debu Mukherjee
Kenneth G. Kowalski
David C. Jordan
机构
[1] Pfizer Corporation Pharmacometrics,Biostatistics
[2] PPD,GPRD Statistics
[3] Abbott Laboratories,undefined
关键词
population modeling; pharmacodynamics; indirect response models; differential equations; dose–effect analysis; NONMEM;
D O I
暂无
中图分类号
学科分类号
摘要
When data fail to support fully mechanistic models, alternative modeling strategies must be pursued. Simpler, more empirical models or the fixing of various rate constants are necessary to avoid over-parameterization. Fitting empirical models can dilute information, limit interpretation, and cloud inference. Fixing rate constants requires external, relevant, and reliable information on the mechanism and can introduce subjectivity as well as complicate determining the validity of model extrapolation. Furthermore, both these methods ignore the possibility that failure of the data to support the mechanistic model could contain information about the pharmacodynamic process. If the pathway has processes with “fast” dynamics, these steps could collapse yielding parametrically simpler classes of models. The collapsed models would retain the mechanistic interpretation of the full model, which is crucial for performing substantive inference, while reducing the number of parameters to be estimated. These concepts are illustrated through their manifestations on the dose–effect relationship and ensuing dose selection for a proof of concept study. Specifically, a mechanistic model for a selective irreversible antagonist was posited and candidate classes of models were derived utilizing “fast dynamics” assumptions. Model assessment determined the rate-limiting step facilitating pertinent inference with respect to the mechanism. For comparison, inference using a more empirical modeling strategy is also presented. A general solution for the collapse of the typical PK–PD model differential equations is provided in Appendix A
引用
收藏
页码:501 / 520
页数:19
相关论文
共 50 条
  • [1] Collapsing mechanistic models: An application to dose selection for proof of concept of a selective irreversible antagonist
    Hutmacher, MM
    Mukherjee, D
    Kowalski, KG
    Jordan, DC
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2005, 32 (3-4) : 501 - 520
  • [2] Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues
    Qian H. Li
    Qiqi Deng
    Naitee Ting
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 1001 - 1005
  • [3] Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues
    Li, Qian H.
    Deng, Qiqi
    Ting, Naitee
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (05) : 1001 - 1005
  • [4] A User-Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline
    Koldeweij, Charlotte
    Dibbets, Caroline
    Franklin, Bryony D.
    Scheepers, Hubertina C. J.
    de Wildt, Saskia N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (01) : 214 - 224
  • [5] Genomic selection in western redcedar: from proof of concept to operational application
    Gamal El-Dien, Omnia
    Shalev, Tal J.
    Yuen, Macaire M. S.
    van der Merwe, Lise
    Kirst, Matias
    Yanchuk, Alvin D.
    Ritland, Carol
    Russell, John H.
    Bohlmann, Joerg
    NEW PHYTOLOGIST, 2024, 244 (02) : 588 - 602
  • [6] Application of a dual mechanistic approach to support bilastine dose selection for older adults
    Kim, Chaejin
    Lo Re, Valentina
    Rodriguez, Monica
    Lukas, John C.
    Leal, Nerea
    Campo, Cristina
    Garcia-Bea, Aintzane
    Suarez, Elena
    Schmidt, Stephan
    Vozmediano, Valvanera
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 1006 - 1017
  • [7] A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials
    Hall, DB
    Meier, U
    Diener, HC
    CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 349 - 364
  • [8] Application of machine learning models to animal health pharmacovigilance: A proof-of-concept study
    Whittle, Edward
    Novotny, Mark J.
    McCaul, Sean P.
    Moeller, Fabian
    Junk, Malte
    Giraldo, Camilo
    O'Gorman, Michael
    de Chenu, Christian
    Dzavan, Pavol
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2023, 46 (06) : 393 - 400
  • [9] Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
    Meng, Amy
    Humeniuk, Rita
    Jurgensmeier, Juliane M.
    Hsueh, Chia-Hsiang
    Matzkies, Franziska
    Grant, Ethan
    Hoa Truong
    Billin, Andrew N.
    Yu, Helen
    Feng, Joy
    Kwan, Ellen
    Tarnowski, Thomas
    Nelson, Cara H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (02) : 416 - 424
  • [10] Proof of the monotonicity of grid size and its application in grid-size selection for mesoscale models
    Chengxin Wang
    Shouting Gao
    Lingkun Ran
    Li Liang
    Advances in Atmospheric Sciences, 2015, 32 : 1005 - 1015